<?xml version='1.0' encoding='UTF-8' ?>
<ec-patent-document file='EC_SP17026748_20180329.xml' country='EC' doc-number='SP17026748' kind='A' date-published='20180329' lang='ES' date-produced='20190116'>
<bibliographic-data id='bibl' doc-number='SP17026748' country='EC' lang='es'>
<publication-reference><document-id ><country>EC</country><doc-number>SP17026748</doc-number><kind>A</kind><date>20180329</date></document-id></publication-reference>
<classification-ipcr><classification-ipc sequence='1'><section> </section><class> </class><subclass> </subclass><main-group> </main-group><subgroup> </subgroup><edition> </edition><ipc-version-indicator><date> </date></ipc-version-indicator><classification-level>C07D401/04_A61P35/00_A61K31/47</classification-level><symbol-position> </symbol-position><classification-value> </classification-value></classification-ipc></classification-ipcr>
<application-reference> <document-id><country>EC</country><doc-number>IEPI201726748</doc-number><date>20170428</date></document-id></application-reference>
<priority-claims>
<priority-claim sequence='1' kind='National'><doc-number>62/073,325</doc-number><date>20141031</date><country>US</country></priority-claim>
</priority-claims>
<parties><applicants>
<applicant sequence='1' designation='all' app-type='applicant'><addressbook><name>GENOSCIENCE PHARMA</name><address><street>10, rue d'Iena, 13006 Marseille, France</street><country>FR</country></address></addressbook></applicant>
</applicants>
<inventors>
<inventor sequence='1' designation='all'><addressbook><name>DAMIANO LICENSING B.V</name><address><street>STRAWINSKYLAAN 1143, 1077 XX AMSTERDAM, PA?SES BAJOS</street><country>NL</country></address></addressbook></inventor>
<inventor sequence='2' designation='all'><addressbook><name>Tinya ABRAMS</name><address><street>c/o Novartis Institutes for Biomedical Research, Inc.  250 Massachusetts, Avenue Cambridge Massachusetts 02139  United States of America</street><country>US</country></address></addressbook></inventor>
<inventor sequence='3' designation='all'><addressbook><name>KALVISTA PHARMACEUTICALS LIMITED</name><address><street>Building 227, Tetricus Science Park, Porton Down, Salisbury SP4 0JQ, Reino Unido</street><country>GB</country></address></addressbook></inventor>
<inventor sequence='4' designation='all'><addressbook><name>ZHEJIANG LIGHT INDUSTRIAL PRODUCTS IMPORT   EXPORT CORPORATION </name><address><street>199 QingChun Road, HangZhou, China.</street><country>CN</country></address></addressbook></inventor>
<inventor sequence='5' designation='all'><addressbook><name>Steven COHEN </name><address><street>c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, California 92121  United States of America</street><country>US</country></address></addressbook></inventor>
<inventor sequence='6' designation='all'><addressbook><name>BRUN, Sonia</name><address><street>Résidence les Fleurs - Appartement B201 - 115, rue Isaac Newton - 13100 Aix-en-Provence, France</street><country>FR</country></address></addressbook></inventor>
<inventor sequence='7' designation='all'><addressbook><name>AEROVIAS DEL CONTINENTE AMERICANO S.A. AVIANCA</name><address><street>Carrera 51B No. 80-58, Local 104, oficinas 1207, 1208 y 1209. Barranquilla</street><country>CO</country></address></addressbook></inventor>
</inventors><agents>
</agents></parties>
<invention-title lang='es'>DIAMINO-QUINOLEÍNA 2,4 SUSTITUIDA COMO NUEVOS AGENTES ANTICANCERÍGENOS</invention-title>
</bibliographic-data>
<abstract lang='es'>El presente invento se relaciona a derivados novedosos de amino-quinoleína 2-primario amino-4-secundario, su manufactura, composiciones farmacéuticas que los comprendan y su uso como medicamentos. Los compuestos activos de la presente invención son útiles para el tratamiento y prevención de enfermedades proliferativas neoplásicas y no neoplásicas.</abstract>
</ec-patent-document>
